Sonoma BioTherapeutics
1 Letterman Dr
San Francisco
CA
94129
United States
2 articles with Sonoma BioTherapeutics
-
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases
2/6/2020
Company founded by four pioneers of Treg cell biology and cell therapy and financed by a syndicate of leading biotech investors
-
Updated: Parker Institute CEO Jeffrey Bluestone Steps Down to Launch Sonoma Biotherapeutics
2/6/2020
Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, has stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.